High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight
Arcturus Therapeutics Analyst Ratings
This Arcturus Therapeutics Holdings Insider Reduced Their Stake By 18%
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers
カナコード・ジェニュイティはアークトゥルス・セラピューティクス(ARCT.US)のレーティングを強気に据え置き、目標株価を74ドルに据え置いた
カナコード・ジェニュイティのアナリストWhitney Ijemは$Arcturus Therapeutics(ARCT.US)$のレーティングを強気に据え置き、目標株価を74ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は53.7%、平均リターンは10.4%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate
Arcturus Gets FDA Clearance for H5N1 Avian Flu Vaccine Study
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript Summary
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript
アークトゥルス・セラピューティクス | 10-Q:Q3 2024 四半期報告書
Arcturus Therapeutics: Q3 Earnings Snapshot
Arcturus Therapeutics GAAP EPS of -$0.26 Beats by $0.88, Revenue of $41.67M Beats by $5.08M
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Posts Q3 Revenue $41.7M
Arcturus Therapeutics 3Q Loss/Shr 26c >ARCT
Here Are the Major Earnings After the Close Today